Christina S. Chu, MD
Last Modified: April 21, 2002
Dear OncoLink "Ask The Experts,"
Have you or any of your colleagues used Gemzar in the treatment of ovarian cancer? I would like to know of any stats on the success of this chemotherapy for ovarian cancer.
Christina S. Chu, MD, Assistant Professor of the Division of Gynecologic Oncology at the University of Pennsylvania Health System, responds:
Gemcitabine (brand name Gemzar®) is generally used as a second-line treatment for recurrent or persistent ovarian cancer. In general, the rate of response to this chemotherapy is about 15-20%. This means that 15-20% of patients with recurrent or persistent disease will have shrinkage of their tumor after treatment with gemcitabine.
Oct 18, 2013 - For patients with metastatic pancreatic cancer, treatment with albumin-bound paclitaxel plus gemcitabine is more effective than gemcitabine alone, according to a study published online Oct. 16 in the New England Journal of Medicine.
May 12, 2011
Jun 20, 2012